TASSMerck Receives Two More Patents for CRISPR TechnologyTASSDARMSTADT, Germany, Feb. 20, 2018 /PRNewswire/ — Merck, a leading science and technology company and leader in genome editing, today announced that the Korean Intellectual Property Office an… Continue reading
CAR T cells appear effective in leukemia subtypeHealioATLANTA — Chimeric antigen receptor T cells have been at the forefront of immunotherapy for the treatment of B-cell malignancies, according to Amelia A. Langston, MD, medical director and section ch… Continue reading
Baylor College of Medicine News (press release) |
Global Stem Cells Banking Market — Revolutionary Way to Cure Life-Threatening Diseases through Stem Cell Banking …
GlobeNewswire (press release) NEW YORK, Feb. 20, 2018 (GLOBE NEWSWIRE) — The global stem cell banking market is expected to grow significantly from USD 1,380 million in 2016 to USD 3,761 million in 2023, at a CAGR of 15.5% from 2017 to 2023. Factors propelling the growth of the … Ethicists explore ways to regulate unproven stem cell therapiesBaylor College of Medicine News (press release) Astellas adding ‘off-the-shelf’ stem cell tech in $102.5m acquisitionBioPharma-Reporter.com Stem–cell therapy used to restore joint healthBrunswick News PR Newswire (press release) –Facts of Week all 25 news articles » |
BSA bureau |
MilliporeSigma Receives Two More Patents for CRISPR Technology
Markets Insider BURLINGTON, Mass., Feb. 20, 2018 /CNW/ — MilliporeSigma, a leader in genome editing, today announced that the Korean Intellectual Property Office and the Israel Patent Office have each issued notices granting MilliporeSigma’s patent applications for … Merck Receives Two More Patents for CRISPR TechnologyPR Newswire UK (press release) |
|
MilliporeSigma Receives Two More Patents for CRISPR Technology
Canada NewsWire (press release) BURLINGTON, Mass., Feb. 20, 2018 /CNW/ — MilliporeSigma, a leader in genome editing, today announced that the Korean Intellectual Property Office and the Israel Patent Office have each issued notices granting MilliporeSigma’s patent applications for … |
Labiotech.eu (blog) |
This Gene Therapy for Vision Loss is Safe and Effective After Two Years
Labiotech.eu (blog) The results of a long-term follow-up suggest that GenSight’s gene therapy for Leber hereditary optic neuropathy can provide safe and effective treatment for the genetic cause of vision loss. GenSight develops gene therapies to preserve or restore … GenSight Biologics Announces Publication of Positive Data from Phase I/II Trial and Long-Term Follow-up of GS010 in …Business Wire (press release) |
Labiotech.eu (blog) |
This Gene Therapy for Vision Loss is Safe and Effective After Two Years
Labiotech.eu (blog) The results of a long-term follow-up suggest that GenSight’s gene therapy for Leber hereditary optic neuropathy can provide safe and effective treatment for the genetic cause of vision loss. GenSight develops gene therapies to preserve or restore … GenSight Biologics Announces Publication of Positive Data from Phase I/II Trial and Long-Term Follow-up of GS010 in …Business Wire (press release) |